- Nachrichtendetail
-
23.04.2024 13:03:39 - dpa-AFX: *NEUROCRINE BIOSCIENCES SAYS PHASE 2 SAVITRI STUDY MEETS PRIMARY ENDPOINT IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
NEUROCRINE BIOSCI. DL-001 | 900964 | Frankfurt | 124,400 | 21.06.24 08:03:28 | +3,550 | +2,94% | 0,000 | 0,000 | 124,400 | 124,400 |
|
TAKEDA PHARM.CO.LTD. | 853849 | Frankfurt | 23,580 | 21.06.24 09:59:34 | +0,150 | +0,64% | 0,000 | 0,000 | 23,580 | 23,580 |
